CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, engages in the research, development, manufacture, commercialization, marketing, and sale of health and agriculture-related products in the Asia Pacific and North America. More Details
Second-rate dividend payer and overvalued.
Share Price & News
How has CK Life Sciences Int'l. (Holdings)'s share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 775 is less volatile than 75% of Hong Kong stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: 775's weekly volatility (4%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 775 underperformed the Hong Kong Biotechs industry which returned 59.2% over the past year.
Return vs Market: 775 underperformed the Hong Kong Market which returned 28.6% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is CK Life Sciences Int'l. (Holdings)'s share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 weeks ago | Simply Wall StCK Life Sciences Int'l., (Holdings) Inc. (HKG:775) Delivered A Weaker ROE Than Its Industry
2 months ago | Simply Wall StIf You Had Bought CK Life Sciences Int'l. (Holdings) (HKG:775) Shares Five Years Ago You'd Have Earned 45% Returns
3 months ago | Simply Wall StWhat Kind Of Shareholders Hold The Majority In CK Life Sciences Int'l., (Holdings) Inc.'s (HKG:775) Shares?
Is CK Life Sciences Int'l. (Holdings) undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 775 (HK$0.81) is trading above our estimate of fair value (HK$0.36)
Significantly Below Fair Value: 775 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 775 is poor value based on its PE Ratio (62.2x) compared to the HK Biotechs industry average (40.5x).
PE vs Market: 775 is poor value based on its PE Ratio (62.2x) compared to the Hong Kong market (11.7x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 775's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 775 is good value based on its PB Ratio (1.6x) compared to the HK Biotechs industry average (3.4x).
How is CK Life Sciences Int'l. (Holdings) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CK Life Sciences Int'l. (Holdings) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has CK Life Sciences Int'l. (Holdings) performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 775 has a large one-off gain of HK$148.4M impacting its December 31 2020 financial results.
Growing Profit Margin: 775's current net profit margins (2.5%) are lower than last year (3.7%).
Past Earnings Growth Analysis
Earnings Trend: 775's earnings have declined by 9.6% per year over the past 5 years.
Accelerating Growth: 775's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 775 had negative earnings growth (-30.9%) over the past year, making it difficult to compare to the Biotechs industry average (17.5%).
Return on Equity
High ROE: 775's Return on Equity (2.7%) is considered low.
How is CK Life Sciences Int'l. (Holdings)'s financial position?
Financial Position Analysis
Short Term Liabilities: 775's short term assets (HK$3.3B) exceed its short term liabilities (HK$915.6M).
Long Term Liabilities: 775's short term assets (HK$3.3B) do not cover its long term liabilities (HK$6.3B).
Debt to Equity History and Analysis
Debt Level: 775's debt to equity ratio (118.7%) is considered high.
Reducing Debt: 775's debt to equity ratio has increased from 98.4% to 118.7% over the past 5 years.
Debt Coverage: 775's debt is not well covered by operating cash flow (6%).
Interest Coverage: 775's interest payments on its debt are not well covered by EBIT (0.7x coverage).
What is CK Life Sciences Int'l. (Holdings) current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 775's dividend (1.23%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (1.96%).
High Dividend: 775's dividend (1.23%) is low compared to the top 25% of dividend payers in the Hong Kong market (5.97%).
Stability and Growth of Payments
Stable Dividend: 775's dividends per share have been stable in the past 10 years.
Growing Dividend: 775's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: At its current payout ratio (76.7%), 775's payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alan Abel Yu (64 yo)
Mr. Ying Choi Yu, also known as Alan Abel, has been a Chief Executive Officer at CK Life Sciences Int'l., (Holdings) Inc. since September 1, 2020 and serves as its Vice President and Executive Director. He...
CEO Compensation Analysis
Compensation vs Market: Alan Abel's total compensation ($USD1.78M) is above average for companies of similar size in the Hong Kong market ($USD440.00K).
Compensation vs Earnings: Alan Abel's compensation has been consistent with company performance over the past year.
Experienced Management: 775's management team is seasoned and experienced (12.8 years average tenure).
Experienced Board: 775's board of directors are seasoned and experienced ( 16.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
CK Life Sciences Int'l., (Holdings) Inc.'s company bio, employee growth, exchange listings and data sources
- Name: CK Life Sciences Int'l., (Holdings) Inc.
- Ticker: 775
- Exchange: SEHK
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$7.785b
- Shares outstanding: 9.61b
- Website: https://www.ck-lifesciences.com
Number of Employees
- CK Life Sciences Int'l., (Holdings) Inc.
- 2 Dai Fu Street
- Tai Po Industrial Estate
- Tai Po
- New Territories
- Hong Kong
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, engages in the research, development, manufacture, commercialization, marketing, and sale of health and agriculture-related products...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/04/11 10:01|
|End of Day Share Price||2021/04/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.